The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 10 of 12532
Back to Result List

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation

Please always quote using this URN: urn:nbn:de:bvb:20-opus-164506
  • Current guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) orCurrent guidelines recommend consolidation with autologous stem cell transplantation (autoSCT) after induction chemotherapy for most patients with peripheral T-cell lymphoma (PTCL). This assumption is based on five prospective phase II studies, three of which included <50 patients with limited follow-up. Here we present the final analysis of the prospective German study. The treatment regimen consisted of four to six cycles of CHOP chemotherapy followed by mobilizing therapy and stem cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemo(radio)therapy and autoSCT. From January 2001 to July 2010, 111 patients were enrolled in the study. The main subgroups were PTCL not specified (n=42) and angioimmunoblastic T-cell lymphoma (n=37). Seventy-five (68%) of the 111 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the complete response rate after myeloablative therapy was 59%. The estimated 5-year overall survival, disease-free survival and progression-free survival rates were 44%, 54% and 39%, respectively. The results of this study confirm that upfront autoSCT can result in long-term remissions in patients with all major subtypes of PTCL and therefore should be part of first-line therapy whenever possible.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: M. Wilhelm, M. Smetak, P. Reimer, E. Geissinger, T. Ruediger, B. Metzner, N. Schmitz, A. Engert, K. Schaefer-Eckart, J. Birkmann
URN:urn:nbn:de:bvb:20-opus-164506
Document Type:Journal article
Faculties:Medizinische Fakultät / Pathologisches Institut
Language:English
Parent Title (English):Blood Cancer Journal
Year of Completion:2016
Volume:6
Pagenumber:e452
Source:Blood Cancer Journal (2016) 6, e452
DOI:https://doi.org/10.1038/bcj.2016.63
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 616 Krankheiten
Tag:Chemotherapy
Release Date:2020/01/08
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International